462 related articles for article (PubMed ID: 29238906)
21. [Dendritic cell and cancer immune checkpoint].
Kubo T; Hirohashi Y; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(5):468-472. PubMed ID: 27795504
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
24. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
Teng F; Kong L; Meng X; Yang J; Yu J
Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
[TBL] [Abstract][Full Text] [Related]
26. Endocrine complications of cancer immunotherapy.
Król A; Gawlik T; Jarząb B
Endokrynol Pol; 2018; 69(6):722-733. PubMed ID: 30618030
[TBL] [Abstract][Full Text] [Related]
27. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
28. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
[TBL] [Abstract][Full Text] [Related]
29. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
30. Vaccines versus immunotherapy: overview of approaches in deciding between options.
Dalgleish AG
Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
[TBL] [Abstract][Full Text] [Related]
31. Therapy implications of the role of interleukin-2 in cancer.
Lissoni P
Expert Rev Clin Immunol; 2017 May; 13(5):491-498. PubMed ID: 27782752
[TBL] [Abstract][Full Text] [Related]
32. Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.
Spallarossa P; Meliota G; Brunelli C; Arboscello E; Ameri P; Dessalvi CC; Grossi F; Deidda M; Mele D; Sarocchi M; Bellodi A; Madonna R; Mercuro G
Med Res Rev; 2018 Sep; 38(5):1447-1468. PubMed ID: 29283446
[TBL] [Abstract][Full Text] [Related]
33. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.
Alhusseini M; Samantray J
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):267-269. PubMed ID: 28073132
[No Abstract] [Full Text] [Related]
34. [Management of immune-related adverse events during treatment with immune checkpoint inhibitors].
Queirolo P; Spagnolo F
Recenti Prog Med; 2016 Aug; 107(8):407-13. PubMed ID: 27571555
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
36. Toxicity profiles of immunotherapy.
Cousin S; Seneschal J; Italiano A
Pharmacol Ther; 2018 Jan; 181():91-100. PubMed ID: 28716652
[TBL] [Abstract][Full Text] [Related]
37. The development of immunotherapy in older adults: New treatments, new toxicities?
Helissey C; Vicier C; Champiat S
J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
[TBL] [Abstract][Full Text] [Related]
38. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
39. Future approaches in immunotherapy.
Rini B
Semin Oncol; 2014 Oct; 41 Suppl 5():S30-40. PubMed ID: 25438998
[TBL] [Abstract][Full Text] [Related]
40. [Endocrinopathies induced by immune checkpoint inhibitors].
Jaafar J; Mavromati M; Philippe J
Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
